ThinPrep Pap Test Offers Improved Slide Preparation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System for cervical cancer screening has received FDA approval and is now available. The system offers an improved method of preparing Pap smears over the conventional method, leading to fewer retests due to compromised smears and potentially fewer missed abnormalities.

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System forcervical cancer screening has received FDA approval and is nowavailable. The system offers an improved method of preparing Papsmears over the conventional method, leading to fewer retestsdue to compromised smears and potentially fewer missed abnormalities.

With the ThinPrep Pap test, the physician collects the cervicalcells in the traditional way, but rather than smearing a smallportion of the cells onto a slide, the physician rinses the cellsfrom the collection device into a vial filled with preservativesolution. This vial is then sent to the lab where the ThinPrep2000 Processor disperses and filters its contents to reduce mucus,blood, and inflammation, and applies a thin, even layer of cellsto a microscope slide.

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content